banner
 
bar

program

slides
bar
 
 

Individualizing Insulin Therapy
in Type 2 Diabetes  

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of diabetes

Release Date

May 14, 2014

Expiration Date

May 14, 2016

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period May 14, 2014 through May 14, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 9 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logo

Supported by an educational grant from
sanofi-aventis U.S. Inc., A SANOFI COMPANY

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

VIVIAN A. FONSECA, MD, FRCP - Program Chair
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association

Grant/Research Support (To Tulane): Grants from Novo-Nordisk, Sanofi-aventis, Eli Lilly, Abbott, Pan American Laboratories, Reata, Endo Barrier
Honoraria: Glaxo Smith Kline, Takeda, Novo Nordisk, Sanofi-aventis, Eli Lilly, Daiichi Sankyo, Pamlabs, Astra-Zeneca, Abbott, Bristol-Myers Squibb, Boehringer Ingelheim



CHARLES F. SHAEFER JR., MD, FACP
Assistant Clinical Professor of Medicine
Medical College of Georgia
Senior Partner, University Physicians
Augusta, Georgia

Consultant: Sanofi-aventis and Sanofi Global, Lilly Pharmaceuticals, BMS/AZ, Vivus Pharmaceuticals
Speaker’s Bureau: Sanofi, Lilly, BMS/AZ, Janssen, Novartis, Forest Pharmaceuticals



LUIGI F. MENEGHINI, MD, MBA
Professor
Department of Internal Medicine
Division of Endocrinology
University of Texas Southwestern Medical Center
Dallas, Texas

Advisory Board: Novo Nordisk, Sanofi, Halozyme, Boehringer Ingelheim/Lilly
Consultant: Novo Nordisk. Sanofi Diabetes



JUAN P. FRIAS, MD, FACE
Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, CA

Grant/Research Support: Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lily & Company, Merck & Company, Inc. , Novo Nordisk, Inc., Sanofi, Janssen, Idenix, AbbVie

Program Managers Disclosure

Gideon Bosker, MD – Reviewer/Planning Committee
Nothing to disclose

Denise Leary – Planning Committee
Nothing to disclose

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Apply national guidelines, including the non-strictly algorithmic and flexibly prescriptive 2012 ADA/EASD Guidelines focused on comprehensive management of diabetes; and identify therapeutic options—number and type of OADs, patient needs and preferences, target goal attainment, and other factors—those oral, insulin-, and/or combined oral-insulin regimens that provide guideline-consistent care for this population.
  • Test for and recognize patients with glycemic dysregulation who are not meeting target goals for HbA1c and/or other targets and who may require initiation or intensification of insulin therapy.
  • Calculate the risks of hypoglycemia in diabetes; counsel their patients on recognizing symptoms of hypoglycemia, and select among therapeutic agents, including insulin-based therapies and combination insulin plus incretin-based treatments that may reduce the risk of hypoglycemia in this patient subgroup.
  • Identify diabetic patients who are on oral antidiabetic therapy, and who have guideline-consistent triggers for initiating insulin, intensifying insulin, or adding insulin to their existing oral regimen.
  • Identify risk factors and predisposing factors in patients with T2D that make them more vulnerable to micro- and macrovacular complications such as CAD, kidney disease, cataracts, PAD, and other sequelae of diabetes.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2014 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

A1c
AACE
AACE/ACE
ACCORD
ADA
ADA/EASD
ADVANCE
Alpha glucosidase inhibitors
Amylin mimetics
Antihyperglycemic
Basal Insulin
biguanides
Biguanides
Bile acid sequentrants
Dapagliflozin
DCCT
Diabetes

Dopamine 2 agonists
DPP-4 inhibitor
DPP4 inhibitors
Dyslipidemia
ESRD
Exenatide
FPG
Glargine
Gliclazide
glimiperide
Glomerulus
GLP agonist
GLP1 receptor agonists
Glucose
GLUT2
glyburide
Glycemia
Glycemic
Glycogenolysis

 

GRADE
HbA1c
HDL
Homeostasis
SGLT2
Hypertension
Hypoglycemia
Hypoglycemia
incretin
Insulin
Insulin detemir
insulinopenia
Kidney
LDL
Meglitines
Metformin
Microalbumin
NHANES
NPH

Obesity
Type 2
Pioglitazone
PPG
prandial
PREMIX
PROACTIVE
SGLT1
Sodium-Glucose Cotransporters
Sulfonlyureas
Sulfonylureas
T2D
T2DM
Thiazolidinedione
troglitazone
TZD
UKPDS
VADT